{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091175","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.072260+00:00","generated_at":"2026-05-31T12:19:49.652998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IDEAYA Q2 net loss $52.8M; darovasertib neoadjuvant UM shows tumor shrinkage; IDE397 39% ORR in MTAP-deletion tumors","bullets":["Q2 net loss $52.8M vs $39.6M in Q1; R&D expenses $54.5M, up from $42.8M.","Cash $952.7M at June 30; July public offering netted $283.8M, extending runway into at least 2028.","Darovasertib in neoadjuvant UM: Phase 2 enrolled >50 patients; median tumor shrinkage ~72% volume; FDA Type C meeting in Q3.","IDE397 in MTAP-deletion tumors: 39% ORR (1 CR, 6 PR), 94% DCR in 18 evaluable patients; selected 30 mg expansion dose.","Entered option/license agreement with Biocytogen for B7H3/PTK7 BsADC; DC nomination targeted H2 2024; potential milestones $406.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091175","json":"https://secwatch.observer/filing/0000950170-24-091175.json","markdown":"https://secwatch.observer/filing/0000950170-24-091175.md","text":"https://secwatch.observer/filing/0000950170-24-091175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024091175/0000950170-24-091175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024091175/idya-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:19:49.652998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}